These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 33313992)
1. Drug repurposing using transcriptome sequencing and virtual drug screening in a patient with glioblastoma. Saeed MEM; Kadioglu O; Greten HJ; Yildirim A; Mayr K; Wenz F; Giordano FA; Efferth T Invest New Drugs; 2021 Jun; 39(3):670-685. PubMed ID: 33313992 [TBL] [Abstract][Full Text] [Related]
2. Drug repurposing for the treatment of glioblastoma multiforme. Abbruzzese C; Matteoni S; Signore M; Cardone L; Nath K; Glickson JD; Paggi MG J Exp Clin Cancer Res; 2017 Nov; 36(1):169. PubMed ID: 29179732 [TBL] [Abstract][Full Text] [Related]
3. Repurposing drugs for glioblastoma: From bench to bedside. Basso J; Miranda A; Sousa J; Pais A; Vitorino C Cancer Lett; 2018 Aug; 428():173-183. PubMed ID: 29729291 [TBL] [Abstract][Full Text] [Related]
4. Effective treatment of a BRAF V600E-mutant epithelioid glioblastoma patient by vemurafenib: a case report. Lin Z; Xu H; Yang R; Li Z; Zheng H; Zhang Z; Peng J; Zhang X; Qi S; Liu Y; Huang G Anticancer Drugs; 2022 Jan; 33(1):100-104. PubMed ID: 34232949 [TBL] [Abstract][Full Text] [Related]
5. Molecular targeted therapy of glioblastoma. Le Rhun E; Preusser M; Roth P; Reardon DA; van den Bent M; Wen P; Reifenberger G; Weller M Cancer Treat Rev; 2019 Nov; 80():101896. PubMed ID: 31541850 [TBL] [Abstract][Full Text] [Related]
6. Repurposing some older drugs that cross the blood-brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma. Rundle-Thiele D; Head R; Cosgrove L; Martin JH Br J Clin Pharmacol; 2016 Feb; 81(2):199-209. PubMed ID: 26374633 [TBL] [Abstract][Full Text] [Related]
7. BRAF VE1 immunoreactivity patterns in epithelioid glioblastomas positive for BRAF V600E mutation. Kleinschmidt-DeMasters BK; Aisner DL; Foreman NK Am J Surg Pathol; 2015 Apr; 39(4):528-40. PubMed ID: 25581727 [TBL] [Abstract][Full Text] [Related]
8. Epithelioid glioblastoma with microglia features: potential for novel therapy. Nakagomi N; Sakamoto D; Hirose T; Takagi T; Murase M; Nakagomi T; Yoshimura S; Hirota S Brain Pathol; 2020 Nov; 30(6):1119-1133. PubMed ID: 32687679 [TBL] [Abstract][Full Text] [Related]
9. Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells. Weber GL; Parat MO; Binder ZA; Gallia GL; Riggins GJ Oncotarget; 2011 Nov; 2(11):833-49. PubMed ID: 22064833 [TBL] [Abstract][Full Text] [Related]
10. Repurposing the serotonin agonist Tegaserod as an anticancer agent in melanoma: molecular mechanisms and clinical implications. Liu W; Stachura P; Xu HC; Umesh Ganesh N; Cox F; Wang R; Lang KS; Gopalakrishnan J; Häussinger D; Homey B; Lang PA; Pandyra AA J Exp Clin Cancer Res; 2020 Feb; 39(1):38. PubMed ID: 32085796 [TBL] [Abstract][Full Text] [Related]
11. From GWAS to drug screening: repurposing antipsychotics for glioblastoma. Lin WZ; Liu YC; Lee MC; Tang CT; Wu GJ; Chang YT; Chu CM; Shiau CY J Transl Med; 2022 Feb; 20(1):70. PubMed ID: 35120529 [TBL] [Abstract][Full Text] [Related]
12. Phenotypic Screening of Chemical Libraries Enriched by Molecular Docking to Multiple Targets Selected from Glioblastoma Genomic Data. Xu D; Zhou D; Bum-Erdene K; Bailey BJ; Sishtla K; Liu S; Wan J; Aryal UK; Lee JA; Wells CD; Fishel ML; Corson TW; Pollok KE; Meroueh SO ACS Chem Biol; 2020 Jun; 15(6):1424-1444. PubMed ID: 32243127 [TBL] [Abstract][Full Text] [Related]
14. Genomic landscape of gliosarcoma: distinguishing features and targetable alterations. Zaki MM; Mashouf LA; Woodward E; Langat P; Gupta S; Dunn IF; Wen PY; Nahed BV; Bi WL Sci Rep; 2021 Sep; 11(1):18009. PubMed ID: 34504233 [TBL] [Abstract][Full Text] [Related]
15. Integrated Proteogenomics Uncover Mechanisms of Glioblastoma Evolution, Pointing to Novel Therapeutic Targets. Li J; Shih LK; Brat DJ Cancer Res; 2024 May; 84(9):1379-1381. PubMed ID: 38330148 [TBL] [Abstract][Full Text] [Related]
16. Xihuang pill potentiates the anti-tumor effects of temozolomide in glioblastoma xenografts through the Akt/mTOR-dependent pathway. Fu J; Zhu SH; Xu HB; Xu YQ; Wang X; Wang J; Kong PS J Ethnopharmacol; 2020 Oct; 261():113071. PubMed ID: 32603676 [TBL] [Abstract][Full Text] [Related]
17. Afatinib and Temozolomide combination inhibits tumorigenesis by targeting EGFRvIII-cMet signaling in glioblastoma cells. Vengoji R; Macha MA; Nimmakayala RK; Rachagani S; Siddiqui JA; Mallya K; Gorantla S; Jain M; Ponnusamy MP; Batra SK; Shonka N J Exp Clin Cancer Res; 2019 Jun; 38(1):266. PubMed ID: 31215502 [TBL] [Abstract][Full Text] [Related]
18. Novel Targeting of Transcription and Metabolism in Glioblastoma. Su YT; Chen R; Wang H; Song H; Zhang Q; Chen LY; Lappin H; Vasconcelos G; Lita A; Maric D; Li A; Celiku O; Zhang W; Meetze K; Estok T; Larion M; Abu-Asab M; Zhuang Z; Yang C; Gilbert MR; Wu J Clin Cancer Res; 2018 Mar; 24(5):1124-1137. PubMed ID: 29254993 [No Abstract] [Full Text] [Related]
19. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma. Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606 [TBL] [Abstract][Full Text] [Related]
20. Toward precision medicine in glioblastoma: the promise and the challenges. Prados MD; Byron SA; Tran NL; Phillips JJ; Molinaro AM; Ligon KL; Wen PY; Kuhn JG; Mellinghoff IK; de Groot JF; Colman H; Cloughesy TF; Chang SM; Ryken TC; Tembe WD; Kiefer JA; Berens ME; Craig DW; Carpten JD; Trent JM Neuro Oncol; 2015 Aug; 17(8):1051-63. PubMed ID: 25934816 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]